Guideline for the prevention of acute chemotherapy‐induced nausea and vomiting in pediatric cancer patients: A focused update

• Published in: Pediatric blood & cancer Vol. 64; no. 10
• Main Authors: Patel, Priya, Robinson, Paula D., Thackray, Jennifer, Flank, Jacqueline, Holdsworth, Mark T., Gibson, Paul, Orsey, Andrea, Portwine, Carol, Freedman, Jason, Madden, Jennifer R., Phillips, Robert, Sung, Lillian, Dupuis, L. Lee
• Format: Journal Article
• Language: English
• Published: United States Wiley Subscription Services, Inc 01.10.2017
• Subjects: Adolescent; Antagonists; Cancer; Chemotherapy; Child; Child, Preschool; Children; Female; guideline; Hematology; Humans; Infant; Isoquinolines - therapeutic use; Male; Nausea; Nausea - chemically induced; Nausea - prevention & control; Neoplasms - drug therapy; Oncology; Palonosetron; Pediatrics; Practice Guidelines as Topic; Quinuclidines - therapeutic use; Serotonin Antagonists - therapeutic use; Serotonin S3 receptors; supportive care; Vomiting; Vomiting - chemically induced; Vomiting - prevention & control; chemotherapy; supportive care; guideline; pediatrics; nausea; vomiting
• ISSN: 1545-5009; 1545-5017; 1545-5017
• DOI: 10.1002/pbc.26542

This update of the 2013 clinical practice guideline provides clinicians with guidance regarding the use of aprepitant and palonosetron for the prevention of acute chemotherapy‐induced nausea and vomiting (CINV) in children. The recommendations were based on three systematic reviews. Substantive changes were made to the guideline recommendations including the inclusion of palonosetron to the 5‐HT3 antagonists recommended for children receiving highly emetogenic chemotherapy (HEC) and the recommendation of aprepitant for children 6 months of age or older receiving HEC. To optimize CINV control in children, future work must focus on closing critical research gaps.